BPC-157 is a synthetic peptide fifteen amino acids long, sequence GEPPPGKPADDAGLV, with a molecular weight of 1419.5 Da. It is described in the literature as a fragment of a protein found in human gastric juice, and essentially everything published about its biological activity comes from rodent and cell-culture work.
That last sentence is the part most pages about this compound leave out, so it is worth stating at the top. This post covers where the sequence actually came from, what the name means, what a certificate measures and what it cannot measure, how the molecule behaves when you handle it, and where the regulatory position sits. It does not cover human use, because there is no human-use evidence to cover.
What does BPC-157 stand for?
"Body Protection Compound." The number 157 is a laboratory designation, not a chemical descriptor — it does not refer to a position in a sequence or a molecular property.
The name came from a research group at the University of Zagreb, who described BPC-157 as a partial sequence of a larger "body protection compound" isolated from human gastric juice. Almost all of the primary literature on the peptide traces back to that group and its collaborators.
This matters more than it sounds. The parent protein has never been independently isolated, sequenced and characterised by another laboratory, and it does not appear in the standard protein databases as a named entry. So the usual framing — "a fragment of a naturally occurring gastric protein" — rests on a single research lineage. The fifteen-residue peptide itself is entirely real and trivially verifiable by mass spectrometry. Its stated origin is the part that has never been reproduced elsewhere.
The sequence
| Position | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Residue | Gly | Glu | Pro | Pro | Pro | Gly | Lys | Pro | Ala | Asp | Asp | Ala | Gly | Leu | Val |
| Letter | G | E | P | P | P | G | K | P | A | D | D | A | G | L | V |
Three features of that sequence explain most of its handling behaviour:
Five prolines, three of them consecutive. Proline is conformationally rigid — its side chain loops back to the backbone nitrogen, so it cannot adopt most of the angles other residues can. A PPP run forces a locally extended, inflexible structure. This is why BPC-157 has no meaningful secondary structure to lose and why it is comparatively robust in solution.
No cysteine. There are no thiols, so there is no disulfide bond to scramble and no oxidation pathway through cysteine. Compare that with the disulphide bridge in oxytocin, where the bond is the structure.
No methionine or tryptophan. The two residues most prone to oxidative damage are both absent, which removes the degradation route that dominates oxidation-prone residues in peptides.
What remains is a short, proline-rich, oxidation-resistant chain. The vulnerable points are the two aspartate residues at positions 10 and 11, where Asp-Gly and Asp-Ala motifs can undergo slow succinimide-mediated rearrangement in aqueous solution — the mechanism described in which residues degrade first.
What the certificate actually measures
Here is the published data for the three lots currently in this catalogue:
| Lot | Size | Purity (RP-HPLC, 214 nm) | Identity | MW | Net content | Endotoxin |
|---|---|---|---|---|---|---|
| BP5-0803 | 5 mg | 99.73% | LC-MS/MS | 1419.5 | 5.33 mg | <0.05 EU/mL |
| BP10-0803 | 10 mg | 99.71% | LC-MS/MS | 1419.5 | 10.44 mg | <0.05 EU/mL |
| BP15-0803 | 15 mg | 99.84% | LC-MS/MS | 1419.5 | 15.75 mg | <0.05 EU/mL |
Read that table in two passes.
The identity line is the one that matters most. LC-MS/MS returning 1419.5 Da says the material in the vial has the mass the sequence predicts. A purity figure alone cannot tell you that — a vial could be 99.8% pure something else entirely and the chromatogram would look immaculate. What LC-MS confirms goes through why mass and purity answer two different questions.
The purity line is an area percent, not a mass fraction. 99.71% means the main peak accounts for 99.71% of the absorbance at 214 nm, not that the powder is 99.71% peptide by weight. HPLC purity as area percent explains the distinction, and net peptide content vs purity covers why the two numbers routinely differ by ten to twenty percent in lyophilized material.
Net content exceeds the label on all three lots. 10.44 mg in a vial labelled 10 mg is deliberate overfill, not a bonus — it compensates for residual moisture and counter-ion mass so the stated quantity is actually present.
What a certificate cannot tell you
A certificate is a snapshot of one lot at one moment, measured by a specific set of tests. For BPC-157 specifically it does not establish:
- That the material will behave as any published study describes
- Anything about activity, potency or biological effect — no certificate tests for function
- Stability beyond the issue date; see where a lyophilized peptide expiry date comes from
- Freedom from every possible contaminant. What a peptide certificate does not test for lists the gaps explicitly
The endotoxin line deserves one clarification, because it is widely misread: <0.05 EU/mL means tested for pyrogens and found below a limit. It is not a sterility claim, and the two are independent. What "non-pyrogenic" means covers why a vial can be sterile and pyrogenic simultaneously.
Handling: what the structure predicts
Lyophilized and stored cold and dry, BPC-157 is among the more forgiving peptides in a catalogue, for the structural reasons above. In solution it is ordinary — the general rules apply rather than any special case.
| Question | What applies |
|---|---|
| Diluent | No unusual requirement; see choosing a peptide diluent |
| Solubility | Readily water-soluble; the acidic Asp/Glu residues help |
| Adsorption | Short and charged, so plastic binding is a real consideration at low concentration — why peptides stick to plastic |
| Freeze-thaw | Aliquot rather than cycle, per aliquoting and freeze-thaw cycles |
| Storage | Standard lyophilized handling, how to store peptide vials |
What the research actually covers
This is where precision matters, because the gap between what the literature contains and what the internet says it contains is unusually wide for this compound.
What exists: a substantial body of rodent work — rats predominantly — reporting effects in models of tendon injury, gastrointestinal lesion, and vascular response, plus in-vitro work on tendon fibroblast outgrowth and migration (Chang et al. 2011). The 2019 Cell and Tissue Research review by Gwyer and colleagues surveys the musculoskeletal animal literature and is the most useful single entry point.
What does not exist: published, peer-reviewed, adequately powered and controlled human clinical trials. Not "few." None that meet that description. Several registry entries and early-phase listings exist without published results.
The distinction carries real weight. An effect in a rat tendon model establishes that something happens in a rat tendon model. It does not establish a mechanism, a dose relationship, a safety profile, or an effect in humans — a point covered generally in why trial data does not transfer.
There is also a concentration problem worth noting: much of the in-vitro work uses concentrations that are difficult to relate to any plausible systemic exposure, which is a common limitation in peptide cell-culture literature rather than a flaw specific to this compound.
Regulatory position
In 2023, following its 503A bulk drug substances review, the FDA placed BPC-157 in Category 2 — substances for which the agency identified significant safety risks, making them unsuitable for use in compounded preparations. It is not an approved drug in the United States, the European Union, or any other major jurisdiction, and it is not a dietary ingredient.
That placement is a regulatory fact about the substance class. It is not a statement about any particular lot, and it is the reason this compound is supplied for laboratory research only. What "research use only" means explains what that designation does and does not do — including the point that the label does not protect marketing that contradicts it.
Common misconceptions
"It's a natural peptide, so it's inherently safe." Two errors at once. Its natural origin rests on a single unreplicated research lineage, and natural origin has never implied safety for anything.
"It's stable because it survives gastric acid." The stability claim in the literature refers to behaviour in gastric juice in specific experimental conditions. It is not a general statement about the molecule, and it tells you nothing about how a reconstituted solution behaves on a bench.
"99% purity means 99% peptide." It means 99% of the chromatogram's absorbance area. See net peptide content vs purity.
"The blend is just the two peptides." For BPC-157 supplied with TB-500, the certificate reports both component masses separately — what a blend certificate shows covers how to read a multi-component report.
Frequently asked questions
Is BPC-157 a real peptide?
Yes, unambiguously. The fifteen-residue sequence is synthesised by standard solid-phase chemistry and confirmed by mass spectrometry at 1419.5 Da. What is contested is the account of its natural origin, not the existence of the molecule.
Why do some sources give a slightly different molecular weight?
Because monoisotopic and average masses differ, and because some sources quote the mass of a salt form rather than the free peptide. The certificates here report 1419.5 for recent lots and 1419.2 for the March lots — that spread reflects instrument and calculation convention, not different material.
What does the "pentadecapeptide" in the name mean?
Fifteen amino acids. Penta (five) plus deca (ten). It is a description of length, nothing more.
Does a high purity figure mean the compound will work?
No. Purity and identity describe what is in the vial. No certificate tests biological activity, and no analytical method on a certificate of analysis is capable of doing so.
Why is there no human clinical evidence?
Running one requires regulatory authorisation, funding, and a sponsor willing to pursue approval. For a compound with no patent position and an FDA Category 2 placement, the commercial incentive to fund that work is largely absent.
How does BPC-157 differ from TB-500?
Entirely different molecules. BPC-157 is 15 residues at 1419.5 Da; TB-500 as supplied is 4964.2 Da, which corresponds to full-length thymosin β4 at 43 residues rather than the short fragment the name implies. They share no sequence and are frequently blended rather than compared.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612-32. doi.org/10.2174/138161211796196936
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 2011;110(3):774-80. doi.org/10.1152/japplphysiol.00945.2010
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research 2019;377(2):153-159. doi.org/10.1007/s00441-019-03016-8
- US Food and Drug Administration. List 2: Bulk Drug Substances for Which FDA Has Identified Safety Risks (section 503A). www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
Every product mentioned is sold for laboratory research use only and is not for human or animal use. Nothing on this page describes or recommends use of the material sold here in humans or animals.
